12:00 AM
May 07, 2012
 |  BC Week In Review  |  Company News  |  Other News

Orion, Mylan, Novartis neurology news

Orion filed a suit in the U.S. District Court for the District of Delaware claiming that an ANDA from Mylan for a generic version of Stalevo levodopa/carbidopa/entacapone infringes Orion's U.S. Patent Nos. 5,446,194; 6,500,867; and 6,797,732 which cover the Parkinson's disease drug. In March, Orion received notice that Mylan submitted the ANDA, which Orion said contains a Paragraph IV notification claiming...

Read the full 294 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >